Publication: Enhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution.
| dc.contributor.author | Yuste, Eloisa | |
| dc.contributor.author | Ruiz-De-León, María J | |
| dc.contributor.author | Casado, José L | |
| dc.contributor.author | Moreno, Ana | |
| dc.contributor.author | Vivancos, María J | |
| dc.contributor.author | Pérez-Elías, María J | |
| dc.contributor.author | Dronda, Fernando | |
| dc.contributor.author | Quereda, Carmen | |
| dc.contributor.author | Sanchez-Merino, Victor | |
| dc.contributor.author | Vallejo, Alejandro | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.date.accessioned | 2026-11-11T13:32:22Z | |
| dc.date.available | 2026-11-11T13:32:22Z | |
| dc.date.issued | 2025-06-13 | |
| dc.description.abstract | Background/objectives: This study aimed to explore how HTLV-2 infection affects the production of broadly neutralizing antibodies (bNAbs) in persons with HIV-1 (PWH) and to assess the impact of boosted protease inhibitors (PIs). Methods: We evaluated broadly neutralizing antibody (bNAb) activity in 65 PWH, which included 27 who were also co-infected with HTLV-2. All participants were former injection drug users with HCV antibodies and were receiving suppressive antiretroviral therapy (ART). Neutralizing activity was assessed against six recombinant HIV-1 viruses that represent five different subtypes. B cell subsets were also analyzed. Results: HTLV-2 co-infection and the lack of ritonavir-boosted protease inhibitors (r-PIs) were both independently associated with higher neutralization scores (p = 0.017 and p = 0.005, respectively). Among those not on r-PIs, individuals co-infected with HTLV-2 showed significantly higher neutralization scores (p = 0.027) and a broader neutralization breadth (83.4% vs. 48.5%, p = 0.015) compared to those infected only with HIV-1. Additionally, HTLV-2 co-infected individuals had more resting memory B cells (p = 0.001) and fewer activated memory B cells (p = 0.017) than the HIV-1 mono-infected individuals. In our multivariate analysis, only HTLV-2 co-infection remained independently associated with neutralization scores (p = 0.027). Elite neutralizers (with a breadth score of ≥10) had more naive B cells and fewer resting memory B cells compared to those with weaker neutralization in both groups. Conclusions: Co-infection with HTLV-2 enhances bNAb production in PWH on suppressive ART and, in particular, in the absence of r-PI regimens. The prominent neutralizing activity corresponded with B cell subset distributions. The results suggest the complexity regarding the interaction between viral co-infections, antiretroviral regimens, and humoral immune compartments and may inform further H1V-1 pathogenesis inquiries or the appropriate design of a vaccine. | |
| dc.description.peerreviewed | Sí | |
| dc.description.sponsorship | This research was partially supported by a grant from Spanish Instituto de Salud Carlos III (PI20CIII/00039) awarded to E.Y. | |
| dc.format.number | 6 | |
| dc.format.volume | 13 | |
| dc.identifier.citation | Yuste, E.; Ruiz-De-León, M.J.; Casado, J.L.; Moreno, A.; Vivancos, M.J.; Pérez-Elías, M.J.; Dronda, F.; Quereda, C.; Sánchez-Merino, V.; Vallejo, A. Enhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution. Vaccines 2025, 13, 639. https://doi.org/10.3390/vaccines13060639 | |
| dc.identifier.doi | 10.3390/vaccines13060639 | |
| dc.identifier.issn | 2076-393X | |
| dc.identifier.journal | Vaccines | |
| dc.identifier.pubmedID | 40573970 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/27823 | |
| dc.language.iso | eng | |
| dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/AESI/PI20CIII%2F00039//Nuevos Abordajes para el Diseño de Inmunógenos para la Inducción de Anticuerpos Neutralizantes de Amplio Espectro anti-VIH-1 Basados en Envueltas Virales Presentadas en VLPs/ | |
| dc.relation.publisherversion | https://doi.org/10.3390/vaccines13060639 | |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología (CNM) | |
| dc.repisalud.institucion | ISCIII | |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | B cell subsets | |
| dc.subject | HIV-1 | |
| dc.subject | HTLV-2 | |
| dc.subject | Neutralizing antibodies | |
| dc.title | Enhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 1e723484-61b4-4f8f-ad19-48873c9050f5 | |
| relation.isAuthorOfPublication | 2c8533e8-d63c-4c22-9a9b-b630525f7153 | |
| relation.isAuthorOfPublication.latestForDiscovery | 1e723484-61b4-4f8f-ad19-48873c9050f5 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication.latestForDiscovery | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isPublisherOfPublication | 30293a55-0e53-431f-ae8c-14ab01127be9 | |
| relation.isPublisherOfPublication.latestForDiscovery | 30293a55-0e53-431f-ae8c-14ab01127be9 |


